Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals

International Journal of Antimicrobial Agents

Volumn 52, Issue 2, 2018, Pages 269-271

  Falagas, Matthew E ^a,b,c   Skalidis, Tilemachos ^d   Vardakas, Konstantinos Z ^a,b   Voulgaris, Georgios L ^a,e   Papanikolaou, Georgios ^f   Legakis, Nicholas ^d   Tsiplakou, S ^g   Papaioannou, V ^g   Trikka Graphakos, E ^h   Charalampakis, N ^h   Sereti, C ^h   Lebessi, E ⁱ   Bozavoutoglou, E ⁱ   Vogiatzakis, E ^j   Moraiti, H ^j   Xanthaki, A ^k   Toutouza, M ^k   Chatzipanagiotou, S ^l   Ioannidis, A ^l   Makri, A ^m   Daskalaki, M ^m   Staikou, E ^m   Tzannetou, K ⁿ   Prifti, H ⁿ   Mentessidou, K ^o   Angelopoulou, K ^o   Dimitrakopoulou, K ^o   Platsouka, E ^p   Skarmoutsou, N ^q   Spiliopoulou, I ^r   Christofidou, M ^r   Triarides, N ^a   Kyriakidou, M ^a   more..

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d IASO   (Greece)

^e 401 GENERAL MILITARY HOSPITAL OF ATHENS   (Greece)

^f Bioprepare Microbiology   (Greece)

^g KAT HOSPITAL   (Greece)

^h THRIASIO GENERAL HOSPITAL   (Greece)

ⁱ P AND A KYRIAKOU CHILDREN S HOSPITAL   (Greece)

^j SOTIRIA GENERAL HOSPITAL   (Greece)

^k IASO GENERAL HOSPITAL   (Greece)

^l NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^m PENTELI CHILDREN S HOSPITAL   (Greece)

ⁿ ALEXANDRA HOSPITAL   (Greece)

^o 'Filoktitis' Recovery and Rehabilitation Center   (Greece)

^p AGIA OLGA HOSPITAL   (Greece)

^q SISMANOGLIO HOSPITAL   (Greece)

^r UNIVERSITY HOSPITAL OF PATRAS   (Greece)

more..

Author keywords

Carbapenem resistant Acinetobacter baumannii; Extensively drug resistant; Fluorocycline; Minocycline; Pandrug resistant; Tigecycline

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AVIBACTAM; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; MEROPENEM; MINOCYCLINE; TIGECYCLINE; TP 6076; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; NAPHTHACENE DERIVATIVE;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; CONTROLLED STUDY; ESCHERICHIA COLI; MIC50; MIC90; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; ACINETOBACTER INFECTION; ANALOGS AND DERIVATIVES; BETA-LACTAM RESISTANCE; CLINICAL TRIAL; DRUG EFFECT; GREECE; GROWTH, DEVELOPMENT AND AGING; HOSPITAL; HOSPITAL PATIENT; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTICENTER STUDY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; COLISTIN; GREECE; HOSPITALS; HUMANS; INPATIENTS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; NAPHTHACENES;

EID: 85048986104     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2018.03.009     Document Type: Article

References (14)

1. Falagas, ME, Karveli, EA, Siempos, II, Vardakas, KZ, Acinetobacter infections: a growing threat for critically ill patients. Epidemiol Infect 136 (2008), 1009–1019.
2. Karageorgopoulos, DE, Falagas, ME, Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 8 (2008), 751–762.
3. Vardakas, KZ, Rafailidis, PI, Konstantelias, AA, Falagas, ME, Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug?. J Infect 66 (2013), 401–414.
4. Falagas, ME, Mavroudis, AD, Vardakas, KZ, The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?. Expert Rev Anti Infect Ther 14 (2016), 747–763.
5. Grossman, TH, Fyfe, C, Kerstein, K, Xiao, X, Sun, C, Newman, J, et al. TP-6076 is efficacious in a mouse pneumonia model with carbapenem-resistant Acinetobacter baumannii (CRAB) and retains potency against common tetracycline-resistance mechanisms. 26th ECCMID, Amsterdam, Netherlands, 2016.
6. Bradford, PA, Petersen, PJ, Young, M, Jones, CH, Tischler, M, O'Connell, J, Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob Agents Chemother 49 (2005), 3903–3909.
7. Clinical and Laboratory Standards Institute. M07-A10: methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. tenth edition, 2015, CLSI, Wayne, PA —.
8. Clinical and Laboratory Standards Institute. M100-S25: performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. 2015, CLSI, Wayne, PA.
9. Sader, HS, Castanheira, M, Flamm, RK, Farrell, DJ, Jones, RN, Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. Antimicrob Agents Chemother 58 (2014), 1684–1692.
10. Jones, RN, Ferraro, MJ, Reller, LB, Schreckenberger, P, Swenson, JM, Sader, HS, Multicenter studies to establish tigecycline disk diffusion susceptibility break points when testing Acinetobacter species. J Clin Microbiol 45 (2007), 227–230.
11. Grossman, TH, Clark, R, Xiao, XY, Fyfe, C, Sutcliffe, J, In vitro activities of novel tetracyclines against molecularly characterized carbapenem-resistant Gram-negative pathogens. 25th ECCMID, Copenhagen, Denmark, 2015.
12. Seifert, H, Stefanik, D, Sutcliffe, J, Higgins, PG, In-vitro activity of the novel fluorocycline TP-6076 against carbapenem nonsusceptible Acinetobacter baumannii. 27th ECCMID, Vienna, Austria, 2017.
13. Fyfe, C, Close, B, Leblanc, G, Newman, J, TP-6076 is active against carbapenem- and polymyxin-resistant Enterobacteriaceae and Acinetobacter baumannii isolates in the FDA-CDC antimicrobial isolate bank panels. 27th ECCMID, Vienna, Austria, 2017.
14. Tsai L, Redican S, P Horn. Safety, tolerability and pharmacokinetics of single doses of TP-6076, a novel fully synthetic tetracycline, in a phase 1 study. Abstract 4806. ASM Microbe, New Orleans, USA 2017.